about
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cellsNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Circulating serologic and molecular biomarkers in malignant melanomaMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerA comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cellsEmergent decision-making in biological signal transduction networksIdentification of BRAF inhibitors through in silico screeningChemChains: a platform for simulation and analysis of biochemical networks aimed to laboratory scientistsDysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesCharacterisation of the vitreous proteome in proliferative diabetic retinopathy.Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersRlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancerCombined anticancer effects of sphingosine kinase inhibitors and sorafenib.Phosphorylation of ASPP2 by RAS/MAPK pathway is critical for its full pro-apoptotic functionCCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.Renal cell carcinoma and the use of sorafenib.A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice.Raf kinases: function, regulation and role in human cancer.KRAS mutant colorectal tumors: past and presentGenetic and biochemical alterations in non-small cell lung cancer.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyUbiquitin pathway and ovarian cancer.Raf kinases: oncogenesis and drug discovery.MEK-1 activates C-Raf through a Ras-independent mechanism.Role of raf-1 kinase in diabetes-induced accelerated apoptosis of retinal capillary cells.Inhibiting kinases in malignant gliomas.Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.Diesel exhaust particles activate the matrix-metalloproteinase-1 gene in human bronchial epithelia in a beta-arrestin-dependent manner via activation of RASAzaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation.Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.PGF(2alpha) stimulates FP prostanoid receptor mediated crosstalk between Ras/Raf signaling and Tcf transcriptional activation.Recent advances in the systemic treatment of metastatic papillary renal cancer.Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancerRLIP76 Targeted Therapy for Kidney Cancer
P2860
Q24602021-AD74FD89-504D-4F0D-BE1C-ECAF62C58BE9Q26796348-B7A42DC3-2F48-49F4-8DE4-2B59C00445A9Q27020946-3F0450B9-7AE8-42D0-B760-7702E97AF7CCQ28076490-B616771E-CE50-41B7-B2CE-1D4E99199443Q28486292-5C73585D-BF07-49B1-8C69-B1DB9D54F361Q29011648-180B1B16-DE7E-43AF-991A-75866AEAFB30Q33368383-491E6793-5AC7-4B87-B9AB-AB40AADA4D27Q33461917-02792BC6-E0F6-4E93-A5F3-167E1E41A2DAQ34139691-EBF0EC30-40F6-4BD6-B035-88AD5FEAD4BDQ34184946-9D919C11-3373-4DAE-B578-63742E804B68Q34206531-688BBB7D-FF0A-48C0-9824-6E1A0A736649Q34451540-F1F7E94F-E560-4D1A-8D22-851D35BEF18CQ34659415-6D982F36-F18D-44C1-9C6A-23146FD0DC4EQ34706060-FA976762-FB69-42E0-9B54-F91B5DF52D29Q34729940-DBD449E8-9E8A-4418-8C97-A2A9723A14CFQ34949678-22442234-28A7-4409-B172-A8BB8C61B03FQ35061442-6E2E15ED-E10E-4826-BC59-F1920958486CQ35122888-70F1BB83-CCEB-4449-BBB0-5E1A707A8BDEQ35166782-19016175-801C-44B0-B6CF-A952C2C65FA0Q35601503-80EDE36F-7942-4555-8B65-16F7C58B0E1EQ36002845-D4078472-0A26-45A3-9133-475011E4755AQ36100844-890E2010-2473-4984-82E2-55F76F45BD40Q36184584-0E73E29D-A551-4C02-A48F-B71159AB46FDQ36278239-49488497-E7AA-4D29-9E76-6281662B7EC1Q36416228-855F7522-BA3A-4826-829B-24B1A329F714Q36559414-472CE6C6-4160-4B42-A5FB-FC7E1E261488Q36717848-7E32E6C5-2BEA-40DE-9F36-3FD9EFE1E75AQ36735369-F87D0136-974B-497C-9F7B-527C63DB22A2Q36764876-F25A3C78-0968-40D7-A1EA-F5F60EB42EE0Q36790872-FBA19898-CC46-46E2-AC9B-58B11CAA730AQ36804407-9CB1EC0F-739A-4E9F-8B25-5957DAE9257BQ36892799-1E1AB35B-77E2-4305-AE83-4A4C5D08F84CQ37122693-90448CBA-F3BB-40E4-88B6-D89B794CD89CQ37142327-3ECBE7B1-AF01-49B2-88AE-021DA00E2290Q37203920-FEB5AA27-3696-4B5F-B819-1565B5EC751DQ37301234-3E5E8506-BD69-4E32-8E51-A509D44EB7AAQ37325934-34CC37EA-AF0D-471F-B78B-38B684A1DDD6Q37411186-B4BB2151-EA72-439E-9806-33C94A6D2587Q37578728-E5DE4B30-4D4E-4156-8B97-7164CCDF81CBQ37741408-14A814B2-0F4F-428B-9342-D63D8DA75E67
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Raf kinase as a target for anticancer therapeutics
@ast
Raf kinase as a target for anticancer therapeutics
@en
Raf kinase as a target for anticancer therapeutics
@nl
type
label
Raf kinase as a target for anticancer therapeutics
@ast
Raf kinase as a target for anticancer therapeutics
@en
Raf kinase as a target for anticancer therapeutics
@nl
prefLabel
Raf kinase as a target for anticancer therapeutics
@ast
Raf kinase as a target for anticancer therapeutics
@en
Raf kinase as a target for anticancer therapeutics
@nl
P1476
Raf kinase as a target for anticancer therapeutics
@en
P2093
Lillian L Siu
Srikala S Sridhar
P304
P356
10.1158/1535-7163.MCT-04-0297
P407
P50
P577
2005-04-01T00:00:00Z